Experimental antiviral for COVID-19 effective in hamster study

MK-4482 shows potential to prevent and treat SARS-CoV-2 infection

Newswise — WHAT: The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists. SARS-CoV-2 is the virus that causes COVID-19. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings.

In their study, published in the journal Nature Communications, the scientists found MK-4482 treatment effective when provided up to 12 hours before or 12 hours after infecting the hamsters with SARS-CoV-2. These data suggest that MK-4482 treatment potentially could mitigate high-risk exposures to SARS-CoV-2, and might be used to treat established SARS-CoV-2 infection alone or possibly in combination with other agents.

The same research group, located at Rocky Mountain Laboratories, part of NIH's National Institute of Allergy and Infectious Diseases in Hamilton, Montana, developed the hamster model last year to mimic SARS-CoV-2 infection and mild disease in people. The University of Plymouth in the United Kingdom collaborated on these most recent studies.

The project involved three groups of hamsters: a pre-infection treatment group; a post-infection treatment group; and an untreated control group. For the two treatment groups, scientists administered MK-4482 orally every 12 hours for three days. At the conclusion of the study, the animals in each of the treatment groups had 100 times less infectious virus in their lungs than the control group. Animals in the two treatment groups also had significantly fewer lesions in the lungs than the control group.

The scientists determined the MK-4482 treatment doses for this study based on previous experiments performed in mouse models of SARS-CoV-1 and MERS-CoV. In those studies, MK-4482 was effective at stopping the viruses from replicating.

With funding support from NIAID, Emory University's Drug Innovation Ventures group in Atlanta developed MK-4482 (also known as molnupiravir and EIDD-2801) to treat influenza. Merck and Ridgeback Biotherapeutics are now jointly developing and evaluating MK-4482 as a potential COVID-19 treatment. The drug is in Phase 2 and 3 human clinical studies.

###

ARTICLES: K Rosenke et al. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nature Communications DOI: 10.1038/s41467-021-22580-8 (2021).

K Rosenke et al. Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infectionEmerging Microbes and Infections DOI: 10.1080/22221751.2020.1858177 (2020).

WHO: Heinz Feldmann, M.D., Ph.D., chief of NIAID's Laboratory of Virology; Michael A. Jarvis, Ph.D., a guest researcher in the Laboratory of Virology from the University of Plymouth; and Kyle Rosenke, Ph.D., Laboratory of Virology, are available to comment on these studies.

CONTACT: To schedule interviews, please contact Ken Pekoc, (301) 402-1663, [email protected].

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5575
Released: 6-May-2021 4:20 PM EDT
How to Win Over Vaccine Skeptics: Live Expert Panel for May 20, 3pm ET
Newswise

How to Win Over Vaccine Skeptics: Live Expert Panel for May 20, 3pm ET

Released: 6-May-2021 2:15 PM EDT
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

After the Most Comprehensive Review to Date, a Panel of Leading Medical Experts Conclude that Ivermectin Should be Systematically and Globally Adopted for the Prevention and Treatment of COVID-19

Released: 6-May-2021 2:10 PM EDT
儿童同样面临COVID-19的长期影响
Mayo Clinic

COVID-19感染可能对部分儿童和青少年,以及成人的健康产生长期影响。虽然大多数COVID-19儿童感染者症状轻微或根本没有症状,但对于任何COVID-19感染者而言,即使病情轻微或没有症状,感染也可能产生长期影响。

Newswise: CSUCIVaxClinic4-29-21.JPG
Released: 6-May-2021 2:05 PM EDT
CSU Expands Vaccine Availability with New Partnerships
California State University (CSU) Chancellor's Office

Many CSU campuses now offer even more options for students and employees to get their COVID-19 shots, thanks to unique partnerships with national pharmacies and local hospitals.

Released: 6-May-2021 1:50 PM EDT
الأطفال أيضًا يواجهون آثارًا طويلة المدى لفيروس كورونا المستجد (كوفيد-19)
Mayo Clinic

مدينة روتشستر، ولاية مينيسوتا ― تؤثر الآثار طويلة المدى لعدوى فيروس كورونا المستجد (كوفيد-19) على صحة بعض الأطفال والمراهقين، وكذا البالغين. في حين أن معظم الأطفال المصابين بعدوى فيروس كورونا المستجد (كوفيد-19) يعانون من أعراض خفيفة أو لا تظهر عليهم أي أعراض على الإطلاق، فإن أي شخص أصيب بفيروس كورونا المستجد (كوفيد-19) - حتى لو كان المرض خفيفًا أو لم تظهر عليه أعراض - قد يُصاب بآثار طويلة المدى.

Released: 6-May-2021 1:35 PM EDT
As crianças também enfrentam efeitos de longo prazo da COVID-19
Mayo Clinic

Os efeitos de longo prazo da infecção por COVID-19 estão afetando a saúde de algumas crianças e adolescentes, bem como de adultos. Embora a maioria das crianças com infecção por COVID-19 tenha sintomas leves ou nenhum sintoma, qualquer pessoa que teve COVID-19, mesmo se leve ou sem sintomas, pode ter efeitos de longo prazo.

Newswise: Retired Nurse Returns to the Front Lines
Released: 6-May-2021 1:25 PM EDT
Retired Nurse Returns to the Front Lines
Rush University Medical Center

During the COVID-19 pandemic, Martha Kuhr, RN, came out of retirement to care for some of Rush University Medical Center's most severe COVID-19 patients in the CVICU.

Released: 6-May-2021 12:40 PM EDT
Achieving high COVID-19 vaccine coverage levels by summer can prevent millions of cases
CUNY Graduate School of Public Health and Health Policy

With around 30 percent of the U.S. population now fully vaccinated, the rate of daily vaccinations has started to slow, raising concerns that greater efforts and investments may be needed to reach higher coverage levels.

Released: 6-May-2021 12:30 PM EDT
Los niños también enfrentan los efectos a largo plazo de la COVID-19
Mayo Clinic

Los efectos a largo plazo de la infección por COVID-19 están repercutiendo en la salud de algunos niños y adolescentes, además de los adultos. Si bien la mayoría de los niños con infección por COVID-19 tienen síntomas leves o no tienen síntomas en absoluto, cualquier persona que haya tenido COVID-19 (incluso si la enfermedad fue leve o no tuvieron síntomas) puede tener efectos a largo plazo.


Showing results

110 of 5575

close
1.78406